Lonsurf meets OS and PFS endpoints in phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Taiho Oncology Inc. and Servier jointly announced the clinical data from the pivotal phase III trial evaluating Lonsurf (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pretreated metastatic gastric/gastroesophageal junction cancers who have progressed or are intolerant to previous lines of therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.
Tucked in at the end of a 20-minute talk that covered paylines, promising young investigators, and precision medicine, NCI Director Anthony G. Letai beefed up the alliteration with two more words that begin with a “p”: prevention and pilot. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login